Aflibercept

Aflibercept is a recombinant fusion protein developed as an inhibitor of vascular endothelial growth factor. It is primarily used in ophthalmology for the treatment of neovascular age-related macular degeneration and other retinal diseases, as well as in oncology for certain metastatic colorectal cancers. The drug functions by binding to VEGF-A, VEGF-B, and placental growth factor, thereby inhibiting abnormal blood vessel growth and leakage. Its development involved collaborative research between Regeneron Pharmaceuticals and Bayer, leading to approvals from regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency.

Medical uses

Aflibercept is indicated for the treatment of neovascular age-related macular degeneration, a leading cause of vision loss in the elderly, as well as macular edema following retinal vein occlusion. It is also approved for diabetic macular edema and diabetic retinopathy in patients with diabetic macular edema. In oncology, it is used in combination with chemotherapy regimens like FOLFIRI for the treatment of metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. The drug is administered via intravitreal injection for ophthalmic uses and intravenous infusion for oncological applications, with treatment schedules studied in pivotal clinical trials such as the VIEW 1 and VIEW 2 studies and the VELOUR trial.

Adverse effects

Common adverse effects associated with intravitreal administration include ocular events such as conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. More serious ocular complications can include endophthalmitis, retinal detachment, and cataract formation. Systemic administration for cancer treatment is associated with a different profile, including hypertension, proteinuria, hemorrhagic events, and gastrointestinal perforation. The drug carries a boxed warning for the risk of arterial thromboembolic events, and its use requires monitoring by healthcare professionals, with safety data continually reviewed by agencies like the FDA and Health Canada.

Pharmacology

Aflibercept acts as a soluble decoy receptor, binding with high affinity to vascular endothelial growth factor-A, VEGF-B, and placental growth factor. This binding prevents these ligands from interacting with their native receptors, VEGFR-1 and VEGFR-2, on endothelial cell surfaces, thereby inhibiting downstream signaling pathways critical for angiogenesis and vascular permeability. Its mechanism is distinct from earlier anti-VEGF agents like bevacizumab and ranibizumab due to its broader ligand specificity. The pharmacokinetic profile varies by route; after intravitreal injection, it is largely confined to the vitreous humor and retina, while systemic administration results in a longer terminal half-life, influencing dosing intervals established in clinical practice.

History

The development of aflibercept originated from research at Regeneron Pharmaceuticals utilizing its proprietary Trap technology platform. Key collaborations with Bayer and sanofi-aventis facilitated clinical development and global commercialization. The drug received its first approval from the U.S. Food and Drug Administration in 2011 for neovascular age-related macular degeneration, following positive results from the VIEW 1 and VIEW 2 clinical trials. Subsequent approvals expanded its indications, including for metastatic colorectal cancer in 2012 based on the VELOUR trial. Its development and patent history have been subjects of legal proceedings, including disputes with companies like Novartis regarding biosimilar entry.

Society and culture

Aflibercept is marketed under the brand names Eylea for ophthalmic use and Zaltrap for oncological use. It has had a significant economic impact on healthcare systems due to its high cost and frequent use, leading to discussions on drug pricing and cost-effectiveness analyses by bodies like the National Institute for Health and Care Excellence in the United Kingdom. The drug's success has contributed substantially to the financial performance of Regeneron Pharmaceuticals and its partners. It has been featured in medical guidelines from organizations such as the American Academy of Ophthalmology and is a subject of ongoing comparative effectiveness research against other anti-VEGF therapies like ranibizumab.

Category:Drugs